Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cxcr4-modified anti-cd19 car t cells
- Development stage
- Phase 1
- Lead developer
- Sichuan University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CXCR4-modified anti-CD19 CAR T cells represent an advanced form of chimeric antigen receptor (CAR) T-cell therapy. This cellular immunotherapy involves genetically engineering a patient's own T cells to express a CAR that specifically targets the CD19 antigen found on B-cell malignancies. The key modification is the incorporation of CXCR4, a chemokine receptor, which serves a dual purpose: enhancing the T cells' ability to migrate towards tumor sites rich in its ligand, CXCL12 (e.g., bone marrow), and providing co-stimulatory signals that augment CAR-T cell activation and cytotoxic function. This modification aims to overcome limitations of conventional CD19 CAR-T cells, such as poor trafficking to certain tumor microenvironments and mechanisms of relapse. Sichuan University is noted as an originator of this type of therapy.
- Other names
- CXCR4 Modified CD19 CAR-TCXCR-4 Modified CD19 CAR-TCXCR 4 Modified CD19 CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on cxcr4-modified anti-cd19 car t cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cxcr4-modified anti-cd19 car t cells.